4//SEC Filing
Martin Daniel C. 4
Accession 0000950170-24-017087
CIK 0001654151other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 4:05 PM ET
Size
9.2 KB
Accession
0000950170-24-017087
Insider Transaction Report
Form 4
Martin Daniel C.
Chief Commercial Officer
Transactions
- Award
Common Stock
2024-02-15+9,725→ 57,385 total - Sale
Common Stock
2024-02-16$15.62/sh−2,267$35,405→ 55,118 total - Award
Stock Option (Right to Buy)
2024-02-15+38,900→ 38,900 totalExercise: $15.92Exp: 2034-02-14→ Common Stock (38,900 underlying)
Footnotes (4)
- [F1]The reporting person was awarded 9,725 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2025, February 15, 2026 and February 15, 2027.
- [F2]This sale was to cover tax liabilities in the vesting of RSUs.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6175 to $15.6177, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
Related Parties
1- filerCIK 0001752827
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 4:05 PM ET
- Size
- 9.2 KB